| pubmed-article:16234823 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16234823 | lifeskim:mentions | umls-concept:C1556094 | lld:lifeskim |
| pubmed-article:16234823 | lifeskim:mentions | umls-concept:C0596382 | lld:lifeskim |
| pubmed-article:16234823 | lifeskim:mentions | umls-concept:C0813148 | lld:lifeskim |
| pubmed-article:16234823 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:16234823 | lifeskim:mentions | umls-concept:C0278801 | lld:lifeskim |
| pubmed-article:16234823 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:16234823 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:16234823 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:16234823 | pubmed:dateCreated | 2005-10-26 | lld:pubmed |
| pubmed-article:16234823 | pubmed:abstractText | The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status </=2 entered the study. Docetaxel 70 mg m(-2) was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39-74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1-50.0%); complete response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3-4 neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients. | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16234823 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16234823 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16234823 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16234823 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:16234823 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:FujiwaraKK | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:YamaguchiSS | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:NodaKK | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:UekiKK | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:NishimuraRR | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:KitagawaRR | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:KuramotoHH | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:NozawaSS | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:UekiMM | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:JoboTT | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:KohnoII | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:KatsumataNN | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:AokiDD | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:EguchiFF | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:SusumuNN | lld:pubmed |
| pubmed-article:16234823 | pubmed:author | pubmed-author:SohdaYY | lld:pubmed |
| pubmed-article:16234823 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16234823 | pubmed:day | 31 | lld:pubmed |
| pubmed-article:16234823 | pubmed:volume | 93 | lld:pubmed |
| pubmed-article:16234823 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16234823 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16234823 | pubmed:pagination | 999-1004 | lld:pubmed |
| pubmed-article:16234823 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:meshHeading | pubmed-meshheading:16234823... | lld:pubmed |
| pubmed-article:16234823 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16234823 | pubmed:articleTitle | Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. | lld:pubmed |
| pubmed-article:16234823 | pubmed:affiliation | Department of Medical Oncology, National Cancer Center Hospital, 104-0045 Tokyo, Japan. nkatsuma@ncc.go.jp | lld:pubmed |
| pubmed-article:16234823 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16234823 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16234823 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
